Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 9/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19464695 | 0.87 | RIPK1 (0.36) | SLC6A2SLC6A4RIPK1NR3C1NR3C2 | |
| SCHEMBL24836099 | 0.85 | CNR2 (0.42) | CNR2CNR1 | |
| SCHEMBL24252081 | 0.81 | SOAT1 (0.35) | CNR2SLC6A2SLC6A4RIPK1NR3C2 | |
| SCHEMBL24121391 | 0.80 | IDO1 (0.36) | RIPK1NR3C1NR3C2 | |
| SCHEMBL19413082 | 0.80 | RIPK1 (0.41) | RIPK1NR3C1NR3C2 | |
| SCHEMBL24333583 | 0.77 | CA2 (0.44) | — | |
| SCHEMBL22435799 | 0.77 | CNR2 (0.41) | CNR2CNR1 | |
| SCHEMBL19965715 | 0.76 | SOAT1 (0.34) | CNR2SLC6A2SLC6A4CNR1RIPK1 | |
| SCHEMBL18649480 | 0.73 | RIPK1 (0.39) | SLC6A2SLC6A4RIPK1NR3C2 | |
| SCHEMBL21474515 | 0.72 | CNR2 (0.54) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | CNR2 528/4885SLC6A2 1080/4885SLC6A4 874/4885 |
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | CNR2 528/4885SLC6A2 1080/4885SLC6A4 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.